Designing idiosyncratic hmPCL -siRNA nanoformulated capsules for silencing and cancer therapy

Abstract In this work, we have designed a siRNA-nanoformulation with mesoporous polycaprolactone ( hmPCL ) for silencing and cancer therapy. Average hollow core size of hmPCL nanocapsules used for nanoformulation is ~ 180 nm with shell thickness of 10-20 nm and mesopore size of ~ 5-10 nm in diameter...

Full description

Saved in:
Bibliographic Details
Published in:Nanomedicine 2016-04, Vol.12 (3), p.579-588
Main Authors: Kumar, Vijay Bhooshon, M. Tech, Medhi, Himadri, M. Tech, Yong, Zhang, PhD, Paik, Pradip, PhD
Format: Article
Language:English
Subjects:
Cancer therapy
Cell Line, Tumor
Hep G2 Cells
Hollow-mesoporous-PCL
Humans
Internal Medicine
Nanocapsules
Nanocapsules - chemistry
Nanoformulation
Neoplasms - genetics
Neoplasms - therapy
Polyesters - chemistry
RNA, Small Interfering - administration & dosage
RNA, Small Interfering - genetics
RNA, Small Interfering - therapeutic use
RNAi Therapeutics - methods
siRNA-silencing
Transfection - methods
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract In this work, we have designed a siRNA-nanoformulation with mesoporous polycaprolactone ( hmPCL ) for silencing and cancer therapy. Average hollow core size of hmPCL nanocapsules used for nanoformulation is ~ 180 nm with shell thickness of 10-20 nm and mesopore size of ~ 5-10 nm in diameter. Idiosyncratic capsules are biocompatible which has been confirmed with normal lymphocyte, K562 leukaemia cancer cells and on HepG2/EGFP cancer cells. In 1 mg of hmPCL capsules up to 400 ng of siRNA can be loaded. This nanoformulation enables to tune the dose dependent delivery up to ~ 93.25% (373 ng) siRNA during therapy. hmPCL -siRNA nanoformulation mediated siRNA transfection on HepG2 cancer cells has been investigated and exhibited 32% silencing activity within 24 h of post transfection. Obtained results directed us that the hmPCL -siRNA nanoformulation could be an efficient tool in siRNA mediated therapy for knocking down the infected cells.
ISSN:1549-9634
1549-9642
DOI:10.1016/j.nano.2015.10.007